Učitavanje...
Immunotherapy for extensive stage small cell lung cancer
Small cell lung cancer (SCLC) is an aggressive malignancy. Until recently the standard of care for newly diagnosed patients with extensive-stage disease was chemotherapy consisting of etoposide plus a platinum (EP). The median overall survival (OS) was only about 10 months with this systemic therapy...
Spremljeno u:
| Izdano u: | J Thorac Dis |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
AME Publishing Company
2020
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7656428/ https://ncbi.nlm.nih.gov/pubmed/33209460 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jtd.2020.01.37 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|